Form 8-K - Current report:
SEC Accession No. 0001104659-25-051847
Filing Date
2025-05-22
Accepted
2025-05-22 08:05:53
Documents
13
Period of Report
2025-05-22
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2515645d2_8k.htm   iXBRL 8-K 27246
2 EXHIBIT 99.1 tm2515645d2_ex99-1.htm EX-99.1 56965
  Complete submission text file 0001104659-25-051847.txt   259135

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA repl-20250522.xsd EX-101.SCH 3017
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE repl-20250522_lab.xml EX-101.LAB 34239
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE repl-20250522_pre.xml EX-101.PRE 22360
15 EXTRACTED XBRL INSTANCE DOCUMENT tm2515645d2_8k_htm.xml XML 3683
Mailing Address 500 UNICORN PARK WOBURN MA 01801
Business Address 500 UNICORN PARK WOBURN MA 01801 (781) 222-9600
Replimune Group, Inc. (Filer) CIK: 0001737953 (see all company filings)

EIN.: 822082553 | State of Incorp.: DE | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-38596 | Film No.: 25974767
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)